BR0011740A - Administração de esteróides androgênicos não-orais a mulheres - Google Patents

Administração de esteróides androgênicos não-orais a mulheres

Info

Publication number
BR0011740A
BR0011740A BR0011740-4A BR0011740A BR0011740A BR 0011740 A BR0011740 A BR 0011740A BR 0011740 A BR0011740 A BR 0011740A BR 0011740 A BR0011740 A BR 0011740A
Authority
BR
Brazil
Prior art keywords
transdermal
oral
shbg
administration
estrogen
Prior art date
Application number
BR0011740-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Theresa Rosario-Jansen
Norman A Mazer
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of BR0011740A publication Critical patent/BR0011740A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0011740-4A 1999-06-11 2000-06-09 Administração de esteróides androgênicos não-orais a mulheres BR0011740A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13885199P 1999-06-11 1999-06-11
US13885499P 1999-06-11 1999-06-11
US13932399P 1999-06-11 1999-06-11
PCT/US2000/015834 WO2000076522A1 (en) 1999-06-11 2000-06-09 Administration of non-oral androgenic steroids to women

Publications (1)

Publication Number Publication Date
BR0011740A true BR0011740A (pt) 2002-05-14

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011740-4A BR0011740A (pt) 1999-06-11 2000-06-09 Administração de esteróides androgênicos não-orais a mulheres

Country Status (25)

Country Link
US (3) US6583129B1 (enExample)
EP (1) EP1189619A4 (enExample)
JP (2) JP5184727B2 (enExample)
KR (2) KR20070063609A (enExample)
CN (1) CN1220491C (enExample)
AR (1) AR024566A1 (enExample)
AU (1) AU775145B2 (enExample)
BR (1) BR0011740A (enExample)
CA (1) CA2376797C (enExample)
CO (1) CO5180583A1 (enExample)
CZ (1) CZ299198B6 (enExample)
HK (1) HK1048269B (enExample)
HU (1) HUP0301813A2 (enExample)
IL (1) IL147010A0 (enExample)
MX (1) MXPA01012769A (enExample)
MY (1) MY126960A (enExample)
NO (1) NO20016046L (enExample)
NZ (1) NZ516502A (enExample)
PE (1) PE20010404A1 (enExample)
PL (1) PL352250A1 (enExample)
SA (1) SA00210404B1 (enExample)
SK (1) SK18212001A3 (enExample)
TR (1) TR200200406T2 (enExample)
TW (1) TWI281398B (enExample)
WO (1) WO2000076522A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
WO2000076522A1 (en) * 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
NZ530227A (en) * 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
DK1411916T3 (da) * 2001-07-09 2008-12-15 Repros Therapeutics Inc Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US20030118633A1 (en) * 2001-11-09 2003-06-26 Ebrahim Versi Combination therapy
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
EP1494679A4 (en) * 2002-04-03 2009-10-28 Barr Lab Inc STEP-BY-STEP ESTROGENTHERAPY
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
WO2003105825A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
DE60303854T2 (de) 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
BRPI0513129A (pt) * 2004-07-14 2008-04-29 Repros Therapeutics Inc método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
CN102406650A (zh) * 2004-10-20 2012-04-11 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
NZ556499A (en) * 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
AU2006218653A1 (en) * 2005-03-02 2006-09-08 Barnett, Gene Ph.D. Pharmaceutically acceptable carrier for ophthalmic compositions
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
RU2008107328A (ru) * 2005-07-27 2009-09-10 Инджениа Текнолоджи Лимитед (Gb) Удостоверение аутентичности
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
US9693953B2 (en) 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
JP5248510B2 (ja) 2006-10-04 2013-07-31 エム アンド ペー パテント アクツィエンゲゼルシャフト 神経伝達物質の鼻腔投与のための徐放性送達システム
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
US9572817B2 (en) * 2008-07-04 2017-02-21 The Heart Research Institute Ltd. Use of androgens for vascular regeneration and endothelial repair
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HK1216502A1 (zh) 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬
MX383926B (es) * 2012-12-05 2025-03-14 Ge Nutrients Inc Uso de estracto de fenogreco para mejorar la libido femenina.
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140274985A1 (en) * 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3737374B1 (en) 2018-01-10 2024-04-03 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
US12186326B2 (en) 2018-07-05 2025-01-07 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US4210664A (en) * 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc., Ste-Foy, Quebec Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
ATE322271T1 (de) * 1993-01-19 2006-04-15 Endorech Inc Therapeutische verwendungen von dehydroepiandrosteron zur behandlung von verminderter libido und osteoporose
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
BR9911115A (pt) 1998-06-11 2001-12-04 Endorech Inc Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol
WO2000076522A1 (en) * 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women

Also Published As

Publication number Publication date
KR20020011437A (ko) 2002-02-08
TR200200406T2 (tr) 2002-06-21
NZ516502A (en) 2004-03-26
CN1367698A (zh) 2002-09-04
HK1048269A1 (en) 2003-03-28
US6583129B1 (en) 2003-06-24
PL352250A1 (en) 2003-08-11
CO5180583A1 (es) 2002-07-30
PE20010404A1 (es) 2001-04-09
CA2376797C (en) 2011-03-22
US20070190120A1 (en) 2007-08-16
HK1048269B (zh) 2006-01-13
HUP0301813A2 (hu) 2003-09-29
KR20070063609A (ko) 2007-06-19
NO20016046L (no) 2002-02-06
WO2000076522A1 (en) 2000-12-21
MXPA01012769A (es) 2003-06-24
TWI281398B (en) 2007-05-21
AR024566A1 (es) 2002-10-16
EP1189619A1 (en) 2002-03-27
NO20016046D0 (no) 2001-12-11
IL147010A0 (en) 2002-08-14
JP2003505345A (ja) 2003-02-12
CA2376797A1 (en) 2000-12-21
US20030153540A1 (en) 2003-08-14
CZ299198B6 (cs) 2008-05-14
AU775145B2 (en) 2004-07-22
CZ20014499A3 (cs) 2002-05-15
AU5475800A (en) 2001-01-02
EP1189619A4 (en) 2004-06-09
MY126960A (en) 2006-11-30
JP5184727B2 (ja) 2013-04-17
US7186706B2 (en) 2007-03-06
SA00210404B1 (ar) 2006-08-21
JP2013049682A (ja) 2013-03-14
US8551516B2 (en) 2013-10-08
CN1220491C (zh) 2005-09-28
SK18212001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
BR0011740A (pt) Administração de esteróides androgênicos não-orais a mulheres
Morley et al. Androgens and women at the menopause and beyond
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
Simon Estrogen replacement therapy: effects on the endogenous androgen milieu
JPH09502194A (ja) 少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤
BR9509155A (pt) Apilcação de inibidores de aromatase para preparação de um medicamento para tratamento de uma deficiência relativa de andrôgeno no homem
US20120225853A1 (en) Hormone replacement therapy and depression
PL356847A1 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
Stuenkel Menopause and estrogen replacement therapy
WO1998006404A1 (en) Combinations for hormone replacement therapy containing a natural oestrogen, a natural progestogen and a natural androgen
EP2687215B1 (en) Mesterolone pharmaceutical composition for dihydrotestosterone deficiencies in woman
US6989163B2 (en) Arrangement to enhance a woman's sexual sensitivity by a combination of phytoestrogens, L-arginine and menthol
RU2234920C2 (ru) Введение непероральным путем андрогенных стероидов женщинам
WO2003041719A1 (en) Method of contraception in mammalian females and pharmaceutical kit for use in such method
Holloway Clinical update on hormone replacement therapy
Rudy Hormone replacement therapy: How to select the best preparation and regimen
Siregar Hormonal therapy for aging process in women
AU2004222794B2 (en) Non-oral androgenic steroids for women
Greenblatt Is there a place for androgens in gynecological disorders?
LICHTEN Estrogen and Alternative Therapy of the Menopausal Patient
TH84327B (th) การใช้และชุดสำเร็จรูปแอนโดรเจนสเตอรอยด์ (Androgenic Steriod) แบบที่ไม่ใช้รับประทานในสุภาพสตรี

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 10(VIII), 11 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.